The Safety, Tolerability, and Preliminary Efficacy of a Gemcitabine-releasing Intravesical System (TAR-200) in American Urological Association–defined Intermediate-risk Non–muscle-invasive Bladder Cancer Patients: A Phase 1b Study-Reference-Cited by-同舟云学术

The Safety, Tolerability, and Preliminary Efficacy of a Gemcitabine-releasing Intravesical System (TAR-200) in American Urological Association–defined Intermediate-risk Non–muscle-invasive Bladder Cancer Patients: A Phase 1b Study

Published:2024-04 Issue: Volume:62 Page:8-15
ISSN:2666-1683
Container-title:European Urology Open Science
language:en
Short-container-title:European Urology Open Science

Author:

P. van Valenberg F. Johannes,van der Heijden Antoine G.,Cutie Christopher J.,Bhanvadia Sumeet,Keegan Kirk A.,Hampras Shalaka,Sweiti Hussein,Maffeo John C.,Jin Shu,Chau Albert,Reynolds Donald L.,Iarossi Crysti,Kelley April,Li Xiang,Stromberg Katharine A.,Michiel Sedelaar J.P.,Steenbruggen Jessica J.O.,Somford Diederik M.,Alfred Witjes J.

Funder

Janssen Research and Development LLC

Publisher

Elsevier BV

Reference37 articles.

1. Cancer statistics, 2023;Siegel;CA Cancer J Clin,2023

2. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

3. Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up;Powles;Ann Oncol,2022

4. European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ);Babjuk;Eur Urol,2022

5. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline;Chang;J Urol,2016

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neue Therapieansätze beim nicht-muskelinvasiven Urothelkarzinom der Harnblase – Ist der Organerhalt auch nach BCG (Bacillus Calmette-Guérin) möglich?;Die Urologie;2024-08-23

2. Deintensification of Treatment for Low-grade Bladder Tumors: A Collaborative Review by the International Bladder Cancer Group (IBCG);European Urology Oncology;2024-08

3. TVNIM, bientôt des alternatives au BCG;Progrès en Urologie - FMC;2024-07

4. Enhancing Therapeutic Efficacy and Safety of Immune Checkpoint Inhibition for Bladder Cancer: A Comparative Analysis of Injectable vs. Intravesical Administration;International Journal of Molecular Sciences;2024-05-01